The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells

被引:137
作者
Zhang, CC
Yang, JM
White, E
Murphy, M
Levine, A
Hait, WN [1 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[3] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA
[4] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA
[5] Inst Canc, New Brunswick, NJ 08901 USA
关键词
drug sensitivity; p53; MAP4; microtubule polymerization;
D O I
10.1038/sj.onc.1201658
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in p53 change the sensitivity to cancer chemotherapeutic drugs, Whereas many drugs, including the vinca alkaloids, often become less effective when p53 is transcriptionally inactivated, several, most notably paclitaxel, may become more effective, In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids, Using murine fibroblasts transfected with MAP4, we directly demonstrated that the changes in drug sensitivity were associated with parallel alterations in drug-induced apoptosis and cell-cycle arrest, Immunofluorescent staining of the microtubule network revealed that cells with increased MAP4 expression displayed an increase in polymerized microtubules and an increased binding of fluorsceinated paclitaxel, Since MAP4 stabilizes polymerized microtubules, overexpression of this gene provides a plausible mechanism to explain the altered sensitivity to microtubule-active drugs in the presence of mutant p53.
引用
收藏
页码:1617 / 1624
页数:8
相关论文
共 43 条
[12]  
HALL PA, 1993, ONCOGENE, V8, P203
[13]   DEFECTS IN A CELL-CYCLE CHECKPOINT MAY BE RESPONSIBLE FOR THE GENOMIC INSTABILITY OF CANCER-CELLS [J].
HARTWELL, L .
CELL, 1992, 71 (04) :543-546
[14]  
Hawkins DS, 1996, CANCER RES, V56, P892
[15]  
HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134
[16]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[17]  
KASTAN MB, 1991, CANCER RES, V51, P6304
[18]  
KONDO S, 1994, CANCER RES, V54, P2928
[19]   CANCER - A DEATH IN THE LIFE OF P53 [J].
LANE, DP .
NATURE, 1993, 362 (6423) :786-787
[20]   P53 MUTATIONS INCREASE RESISTANCE TO IONIZING-RADIATION [J].
LEE, JM ;
BERNSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5742-5746